Federal preemption

I know I have been railing about federal preemption when it has no legitimate legal justification and amounts to a violation of the reserved rights of states set out in the Constitution. But things keep getting worse. A few years ago the Supreme Court affirmed a preemption for injuries at extrahazardous railroad crossings because the government fronted the cost for luminus paint for cross buck signs--with no thought that this would cause all intersections to be safe.

I keep arguing that big pharmacutical companies, which bully FDA to approve medicine not proved to be safe just to get it on the market at break-neck speed, are at the brink of blanket immunity on the frivilous theory of federal preemption.  More evidence keeps piling up that the FDA simply is not equiped to make such decisions. To use the guize of FDA approval to preempt the right of hundreds of thousands of consumers who rely upon the expertise and good faith of the manufactures and subsequently suffer serious conditions and death, is unconstitutional and unethical.

The AP (1/12) reports, "An internal watchdog finds that financial conflicts involving outside researchers who test experimental drugs often remain hidden," and "missing information, loopholes, and weak oversight hamper efforts to uncover financial conflicts involving researchers who test experimental drugs before companies seek government approval." The Health and Human Services inspector general's office's report said, "We found a number of limitations in" the Food and Drug Administration's (FDA) "oversight, leaving FDA unable to determine whether [drug companies] submit financial information for all clinical investigators." According to the AP, "because scientists can be tempted by profits, the government requires disclosure of possible conflicts involving clinical researchers who review medications before drug companies seek FDA approval."

        The FDA "does almost nothing to police the financial conflicts of doctors who conduct clinical trials of drugs and medical devices in human subjects, government investigators are reporting," the New York Times (1/12, A10, Harris) adds. Noted was that, "in percent of clinical trials, the agency did not receive forms disclosing doctors' financial conflicts and did nothing about the problem, according to the investigation, which was conducted by the inspector general of the Department of Health and Human Services and whose results were scheduled to be made public Monday." Another study "by the inspector general last year found that the National Institutes of Health did almost nothing to police the financial conflicts of university professors who received federal money."

Please let me know your feelings. B

FDA

House Energy and Commerce Committee ranking Republican Rep. Joe L. Barton of Texas asked for clarification from the Food and Drug Administration (FDA) this week concerning deaths related to the blood thinner heparin. His letter called into question the adequacy of the agency's review of the deaths. He highlighted previous correspondence from the FDA he received in October that tied two cases of heparin-related deaths to drugs produced by American Pharmaceutical Partners (APP). The APP heparin was not tested for contaminants, according to a FDA letter. FDA spokeswoman Karen Riley gave no substantive response but said "the agency looks forward to clarifying the issue with Barton."

How can the United States Supreme Court or President Bush seriously think that it is a good idea to preempt private law suits against pharmaceutical companies based upon FDA approval. Surely this approach to rights reserved to states and individuals can't be removed in such a cavalier fashion.
 

http://www.bailey-law.com/lawyer-attorney-1215852.html

 

FDA warns bayer about aspirin

The FDA has warned Bayer about its aspirin claims. According to the AP, the FDA "scolded [Bayer] in two warning letters for never submitting proof that its pills -- Bayer Women's Low Dose Aspirin + Calcium and Bayer Aspirin with Health Advantage -- are effective in battling heart disease and osteoporosis."

Janet Woodcock of the FDA's Center for Drug Evaluation and Research said that if these aspirin-containing products are overused or not used properly, consumers can be at risk for internal bleeding and other issues. 

Treatments for these two diseases are required to be reviewed by a board of government scientists and cannot be sold over-the-counter.  

For such "combo pills," dietary supplements and drugs, to be legally marketed, they are subject to approval and generous regulation. 

What comments do you have about the weakness of the FDA and ways we might be able to improve it? Do you agree with me that potential of personal injury lawsuits provide a second line of protection for the consumers?

http://www.bailey-law.com/lawyer-attorney-1215486.html

Fentanyl deaths

Fentanyl is a opiate 100 times more powerful than morphine. Originally this drug was put out as Duragesic®  made by Johnson & Johnson. Although originally it was used in operations, it later was applied in patches for patients with chronic serious pain. Numerous generic versions of the fentanyl patch, including Sandoz (manufactured by Alza), Mylan, Watson and Actavis hit the market. Although intended for only serious pain symtoms, some doctors prescribed it to those not needing such a potent medication. "Fold-over defects" and "stringer leakers" have caused leakage from the patches to over-medicate and kill patients.

A second Public Health Advisory regarding fentanyl pain patches has been issued, which stated that "reports indicate that doctors have inappropriately prescribed the fentanyl patch to patients for acute pain following surgery, for headaches, occasional or mild pain, and other indications for which a fentanyl patch should not be prescribed."

Johnson & Johnson recalled approximately 32 million patches because of possible leak defects. The recall includes Duragesic® and Sandoz brands. Actavis Inc., the United States manufacturing and marketing division of the international generic pharmaceutical company Actavis Group HF announced that 14 lots of fentanyl transdermal system CII patches sold in the United States are being voluntarily recalled.

Once again, patients have relied vainly on the FDA, pharmaceutical companies and their treating physicians for a good faith review of the medications prescribed.  

http://www.bailey-law.com/lawyer-attorney-1215852.html